Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359086 · ClinicalTrials.gov registry record · Phase 2
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00359086: Completed Phase 2 study, sponsored by Mirati Therapeutics.
NCT00359086 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 74 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00359086, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
Interventions
- DRUG MGCD0103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00359086 record still lists
NCT00359086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 1 intervention - of which MGCD0103 is the first listed.
NCT00359086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00359086 about?
NCT00359086 is a clinical study titled "Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma". In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
What is the current status of trial NCT00359086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00359086?
The interventions under investigation include: MGCD0103 (DRUG).
Who is sponsoring clinical trial NCT00359086?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00359086's enrollment target sits among peer trials
74 920th of 2000 higher than 1,077 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia